Clinical trials: Hepatitis C
Hepatitis C Virus (HCV) Infection
Efficacy and Safety of Elbasvir (MK-8742) + Grazoprevir (MK-5172) in Treatment-Naïve/Treatment-Experienced (TN/TE) French Participants With Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection (MK-5172-096)
The purpose of this study was to evaluate the efficacy of 8 and 12 weeks of treatment with a fixed dose combination (FDC) of elbasvir (EBR) 50 mg + grazoprevir (GZR) 100 mg (i.e., MK-5172A) as assessed by the percentage of…
- Trial name
- NCT03111108
- Testing
- EBR/GZR (50 mg/100 mg) FDC
- Where
- 13 sites in France
- Volunteers
- 117 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C Virus Infection
Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/- Ribavirin in Adolescents and Children With Chronic HCV-Infection
The primary objective of the PK Lead-in Phase of the study is to evaluate the steady state pharmacokinetics (PK) and confirm the dose of ledipasvir/sofosbuvir (LDV/SOF) fixed dose combination (FDC) in hepatitis C virus…
- Trial name
- NCT02249182
- Testing
- LDV/SOF, RBV
- Where
- 31 sites in United States, Australia and 2 more
- Volunteers
- 226 people
- Sponsor
- Gilead Sciences
Hepatitis C
Evaluation of MK-1075 in Participants With Hepatitis C Virus (HCV) Infection (MK-1075-002)
The purpose of this study is to evaluate the safety and pharmacokinetics of MK-1075, and to determine the ability of MK-1075 to reduce HCV viral load, following administration of a single dose in HCV-infected participants.
- Trial name
- NCT02392494
- Testing
- MK-1075
- Volunteers
- 9 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C
An Integrated Care Model for Improving Hepatitis C Virus Patient Outcomes
This is a prospective randomized controlled trial comparing two different clinic models for patients with hepatitis C. These patients commonly have mental health problems that are barriers to receiving HCV treatment.
- Trial name
- HCV (NCT00722423)
- Testing
- Integrated care model, Usual Care Model
- Where
- 3 sites in United States
- Volunteers
- 364 people
- Sponsor
- US Department of Veterans Affairs
Hepatitis C Virus
Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Hemophilia
The primary objective for this study is to evaluate the proportion of subjects who achieve SVR12 (HCV RNA < LLOQ (target not detected) at post-treatment follow-up Week 12 in subjects with Genotype(GT)-1b, -4 and GT-2, -3
- Trial name
- MAGNITUDE (NCT01741545)
- Testing
- Pegylated-Interferon-lambda, Ribavirin, Daclatasvir
- Where
- 32 sites in United States, Australia and 6 more
- Volunteers
- 71 people
- Sponsor
- Bristol-Myers Squibb
Chronic Hepatitis C, Decompensated Cirrhosis
A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Ribavirin in Adults With Genotype 1 and Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults With Genotype 4 Chronic Hepatitis C Virus Infection and Decompensated Cirrhosis
The primary objectives of this study are to assess the safety and the SVR12 rate of ombitasvir/paritaprevir/ritonavir and dasabuvir with RBV in GT1-infected participants with decompensated cirrhosis.
- Conditions
- Chronic Hepatitis C, Decompensated Cirrhosis, Hepatitis C Virus
- Trial name
- TURQUOISE-CPB (NCT02219477)
- Testing
- ombitasvir/paritaprevir/ritonavir, dasabuvir, ribavirin
- Volunteers
- 36 people
- Sponsor
- AbbVie
Chronic Hepatitis C Virus (HCV) Infection
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection
The purpose of this study is to evaluate the safety and efficacy of ABT-493/ABT-530 in adults with genotype 2 chronic hepatitis C virus (HCV) infection.
- Trial name
- ENDURANCE-2 (NCT02640482)
- Testing
- ABT-493/ABT-530
- Volunteers
- 304 people
- Sponsor
- AbbVie
HIV, Hepatitis C
Criminal Justice Coordinated Transitional Care
This project aims to enroll 220 incarcerated individuals living with HIV, Hepatitis C (HCV), or history of substance misuse preparing for release into a pilot implementation study to test the feasibility and acceptability of an…
- Conditions
- HIV, Hepatitis C, Substance Use Disorders
- Trial name
- CJC-TraC (NCT05376371)
- Testing
- CJC-TraC
- Where
- 2 sites in United States
- Volunteers
- 219 people
- Sponsor
- University of Wisconsin, Madison
Chronic Hepatitis C
Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin for Treatment-Naïve Hemodialysis Patients With Chronic Hepatitis C
Chronic hepatitis C virus (HCV) infection is common in dialysis patients. Interferon (IFN)-based treatment for chronic hepatitis C has been the mainstay therapy in immunocompetent patients.
- Trial name
- NCT00491244
- Testing
- Peginterferon alfa-2a and ribavirin, Peginterferon alfa-2a
- Where
- Taiwan
- Volunteers
- 377 people
- Sponsor
- National Taiwan University Hospital
Hepatitis C, Chronic
Influence of Ribavirin on the Initial Virological Response in Treatment Naïve Patients With Hepatitis C Genotype 1 Infection
This study examined the influence of ribavirin on the initial virological response in treatment-naïve participants with chronic hepatitis C, genotype 1.
- Trial name
- NCT02716779
- Testing
- Pegylated Interferon (PEG-IFN) alfa-2a, Ribavirin
- Where
- 5 sites in Germany
- Volunteers
- 68 people
- Sponsor
- Hoffmann-La Roche
HCV Infection
Study to Evaluate Effect of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination on the Pharmacokinetics of a Representative Hormonal Contraceptive Medication, Norgestimate/Ethinyl Estradiol
This study will evaluate the effect of sofosbuvir (SOF)/velpatasvir (VEL)/voxilaprevir (VOX) fixed-dose combination (FDC) + voxilaprevir on the pharmacokinetics (PK) of a representative hormonal contraceptive medication…
- Trial name
- NCT02533427
- Testing
- SOF/VEL/VOX, VOX, Norgestimate/ethinyl estradiol
- Where
- New Zealand
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Purpura, Thrombocytopenic, Idiopathic and Hepatitis C
Eltrombopag Phase III Study In Chinese Chronic ITP Patients
This randomized, double-blind and open-label phase III study aimed to determine the efficacy, tolerance and safety of eltrombopag in Chinese chronic primary immune thrombocytopenia (ITP) adult subjects.
- Trial name
- NCT01762761
- Testing
- eltrombopag
- Where
- 18 sites in China
- Volunteers
- 155 people
- Sponsor
- Novartis Pharmaceuticals
Hepatitis C, Chronic, Hepatitis C
Evaluation of Rapid Virologic Response Among HCV Patients Treated With PegIntron and Rebetol in Brazil (Study P05427)
The objective of the study is to evaluate, in each group, the number of participants who achieve rapid virological response (RVR) after 4 weeks treatment with PegIntron and Rebetol.
- Trial name
- APEGIN (NCT00724854)
- Testing
- PegIntron (peginterferon alfa-2b; SCH 54031), Rebetol (ribavirin; SCH 18908)
- Volunteers
- 1,146 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C Virus
A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Co-administered With Ribavirin (RBV) in Adults With Genotype 4 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (AGATE-1)
The purpose of this study in HCV genotype 4-infected participants with compensated cirrhosis is to assess the safety and to compare the percentage of participants achieving a 12-week sustained virologic response (SVR12), [HCV…
- Trial name
- AGATE-1 (NCT02265237)
- Testing
- ombitasvir/paritaprevir/ritonavir, ribavirin
- Volunteers
- 184 people
- Sponsor
- AbbVie
Hepatitis C, Chronic
Multidisciplinary Support Program in Chronic Hepatitis C
Adherence to antiviral treatment in chronic hepatitis C (CHC) is an important factor to achieve sustained virological response (SVR).
- Trial name
- NCT01850745
- Testing
- Multidisciplinary support program
- Where
- Spain
- Volunteers
- 447 people
- Sponsor
- Parc de Salut Mar
Hepatitis C
Safety and Efficacy of Sofosbuvir + Velpatasvir With or Without Ribavirin in Treatment-Naive Adults With Chronic HCV Infection
The primary objectives of this study are to evaluate the antiviral efficacy, safety, and tolerability of sofosbuvir (SOF) + velpatasvir (VEL; GS-5816) with or without ribavirin (RBV) in treatment-naive adults with chronic…
- Trial name
- NCT01858766
- Testing
- SOF, VEL, RBV
- Where
- 51 sites in United States, Puerto Rico
- Volunteers
- 379 people
- Sponsor
- Gilead Sciences
Hepatitis C
Comparison of Telemedicine to Usual Care for HCV Management for Methadone-maintained Individuals
To compare the effectiveness of a patient-centered, opiate agonist treatment (OAT)-integrated telemedicine-based approach for management and delivery of hepatitis C virus (HCV) treatment to persons with substance use disorders…
- Trial name
- NCT02933970
- Testing
- Telemedicine
- Where
- United States
- Volunteers
- 602 people
- Sponsor
- Andrew Talal
Hepatitis C, Chronic
Study of HCV Genotype 1 Patients in the UK Treated With ViraferonPeg and Rebetol (Study P05269)(COMPLETED)
The study is designed as a retrospective data review of medical records from participants selected from specialist secondary and tertiary care centers across the United Kingdom (UK), specializing in Hepatitis C treatment.
- Trial name
- NCT00724373
- Testing
- Peginterferon alfa-2b (SCH 54031), Ribavirin (SCH 18908)
- Volunteers
- 442 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C
Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Chronic Hepatitis C Who Have Not Achieved an Undetectable HCV RNA Level With Previous Interferon Based Therapy
This study will evaluate the efficacy and safety of MP-424 with Peginterferon Alfa-2b and RBV in patients with (Genotype 1) hepatitis C, who did not respond to previous treatment.
- Trial name
- NCT00781274
- Testing
- MP-424, Ribavirin, Peginterferon Alfa-2b
- Where
- Japan
- Volunteers
- 32 people
- Sponsor
- Tanabe Pharma Corporation
Hepatitis C Virus Infection
Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study
The purpose of this study was to evaluate the efficacy and safety of co-administration of glecaprevir (ABT-493)/pibrentasvir (ABT 530) plus sofosbuvir (SOF) plus ribavirin (RBV) in hepatitis C virus (HCV) genotype (GT) 1 …
- Trial name
- MAGELLAN-3 (NCT02939989)
- Testing
- Sofosbuvir, Glecaprevir/Pibrentasvir, Ribavirin
- Where
- 26 sites in United States, Australia and 10 more
- Volunteers
- 33 people
- Sponsor
- AbbVie